Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"Characteristics and Contributing Factors for Difficult to Treat Psoriatic Arthritis- a Comparative Analysis.","authors":"Ong Ping Seung, Lee Pei Jia","doi":"10.1177/24755303251394308","DOIUrl":"10.1177/24755303251394308","url":null,"abstract":"<p><strong>Objective: </strong>To assess the contributing factors and clinical characteristics of difficult-to-treat (D2T) psoriatic arthritis (PsA).</p><p><strong>Patients and methods: </strong>This retrospective cross-sectional study included PsA patients from a tertiary care center. D2T PsA was defined as failure of at least 1 conventional synthetic DMARD (csDMARD) and 2 or more biologic/targeted synthetic DMARDs (b/tsDMARDs) with different mechanisms of action. Baseline demographics, disease duration, and domain involvement were compared across groups.</p><p><strong>Results: </strong>A total of 150 PsA patients were included, with an equal gender distribution and a mean age of 55.9 ± 13.7 years. Patients with D2T PsA had a significantly younger age of onset for both psoriasis and PsA (both <i>P</i> < 0.001), and a higher prevalence of obesity (<i>P</i> = 0.018). Multidomain involvement was prominent, with 93.5% of D2T patients having 3 or more domains affected (<i>P</i> < 0.001). Axial disease, dactylitis, enthesitis, and nail involvement were all significantly more frequent in the D2T group (all <i>P</i> < 0.001). Multivariate analysis identified age, age of psoriasis onset, axial involvement, enthesitis, and nail dystrophy as independent predictors of D2T PsA.</p><p><strong>Conclusion: </strong>D2T PsA is associated with early disease onset, obesity, and extensive multi-domain involvement, particularly axial disease, enthesitis, and nail changes. These findings suggest that specific clinical features and comorbidities may help identify patients at risk of developing D2T PsA. Early recognition of these factors may guide more personalized and aggressive treatment strategies to improve long-term outcomes.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251394308"},"PeriodicalIF":0.0,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Evidence of Brodalumab Safety for the Treatment of Psoriasis.","authors":"Mark Lebwohl, Eingun James Song, Tina Bhutani, Lawrence Green, Abby Jacobson","doi":"10.1177/24755303251382878","DOIUrl":"10.1177/24755303251382878","url":null,"abstract":"<p><p>Plaque psoriasis is a chronic skin disorder involving dysregulated inflammation. While numerous biologic therapies targeting inflammatory mediators have been approved for moderate-to-severe psoriasis, their safety profiles may include an increased risk of adverse events (AEs), such as infections, cardiovascular diseases, and malignancies. Because patients with psoriasis also have increased incidence of comorbidities, long-term real-world AE monitoring is critical to further evaluate the safety of biologic therapies postapproval. Brodalumab is a recombinant, fully human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. The safety profile of brodalumab has been established in clinical trials and industry-sponsored US pharmacovigilance reports. Herein, we summarize AEs reported in nonsponsored open-label and real-world studies of brodalumab. Across all studies, most common AEs were similar to those listed in the brodalumab package insert. While AEs of special interest were not reported comprehensively, their rates were generally low, with 3 cases of major adverse cardiac events, 2 cases of malignancy, 11 cases of depression, and no completed suicides in the overall safety population (N = 1701). There were 6 cases of serious infection and no serious fungal infections. Studies evaluating AEs of interest for brodalumab showed no causal link to suicide and no increase in risk of cardiac events or serious infection compared with other biologics. Together, these studies support a consistent safety profile of brodalumab in real-world use.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251382878"},"PeriodicalIF":0.0,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12552225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Considerations for the Use of Biologic Agents in Psoriasis Patients With a History of Lymphoma.","authors":"Allison Bai, Emily Gartrell, Olivia Whittaker, Jeffrey Sobell","doi":"10.1177/24755303251387119","DOIUrl":"10.1177/24755303251387119","url":null,"abstract":"<p><p><b>Background:</b> Managing psoriasis in patients with a history of lymphoma presents a unique clinical challenge. Psoriasis is associated with significant comorbidities such as cardiovascular disease and inflammatory arthritis, making optimal treatment vital. Systemic treatments like biologic agents may help mitigate these sequelae of systemic inflammation. However, concerns about immunosuppression in the context of lymphoma recurrence and progression complicate therapeutic decisions. <b>Purpose:</b> This review aims to examine the role of IL-12, IL-17, IL-23, and TNF-α in psoriasis and explores the safety of biologic therapies in this population, with a focus on impact on lymphoma recurrence and progression. <b>Research Design:</b> A narrative review of the current medical literature was conducted. <b>Study Sample:</b> The analysis synthesizes evidence from preclinical studies, clinical trials, post-marketing surveillance registries, retrospetive cohort studies, and case reports concerning the use of biologic agents in psoriasis. <b>Data Collection:</b> Relevant literature was identified an analyzed to compare the mechanisms of action, degree of immunosuppression, and available safety data of different biologic agent classes. <b>Results:</b> Based on current evidence, we propose that IL-17 and IL-23 inhibitors as preferred options due to their targeted mechanisms and favorable safety profiles. In contrast, TNF-α inhibitors are less favored due to their comparatively greater immunosuppressive effects and potential association with lymphoma risk. IL-12/23 inhibitors are questionable given their potential impact on tumor immunosurveillance. <b>Conclusion:</b> For psoriasis patients with a history of lymphoma, IL-17 and IL-23 inhibitors represent the most suitable biologic options, while TNF-α inhibitors and IL-12/23 inhibitors should be used with caution. Clinical data overall remains limited, however, as lymphoma patients are routinely excluded from clinical trials. Further research is needed to clarify long-term safety and optimize treatment strategies for this high-risk population.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387119"},"PeriodicalIF":0.0,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12549605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions.","authors":"Melissa C Leeolou, Justin L Jia, Jason Harris, Wilson Liao","doi":"10.1177/24755303251387126","DOIUrl":"10.1177/24755303251387126","url":null,"abstract":"<p><p>In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediaries between insurers, pharmacies, and drug manufactures to influence prescription formularies and generate health savings. We also discuss how controversial PBM practices such as step therapy, prior authorizations, and spread pricing may limit access to biologics and potentially increase cost for patients. Finally, we highlight how dermatologists and national organizations such as the National Psoriasis Foundation can collaborate and advocate for legislative reforms to increase transparency among PBMs.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387126"},"PeriodicalIF":0.0,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12546093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145379162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding \"Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study\".","authors":"Joaquín Borras-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo-Uixeda","doi":"10.1177/24755303251387120","DOIUrl":"10.1177/24755303251387120","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387120"},"PeriodicalIF":0.0,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Trial of Coach-Supported, Smartphone-Delivered Cognitive Behavioral Therapy for Psoriasis With Comorbid Depression.","authors":"John S Barbieri, Megan H Noe, Nora Bensellam, Phoebe Holz, Bruna G O Wafae, Ellen Esther Anshelevich, Jasmine N Williams, Ivar Snorrason, Hilary Weingarden, Oliver Harrison, Sabine Wilhelm","doi":"10.1177/24755303251387099","DOIUrl":"10.1177/24755303251387099","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is associated with increased risk of depression. Although cognitive behavioral therapy (CBT) is an evidence-based treatment, access remains limited.</p><p><strong>Objectives: </strong>To evaluate the feasibility, acceptability, and preliminary efficacy of a smartphone-delivered, coach-led CBT program for depression among individuals with psoriasis.</p><p><strong>Methods: </strong>This single-arm, 8-week pilot study (Mindset trial, NCT06216691) enrolled adults with psoriasis and at least mild depressive symptoms (PHQ-9 ≥5). Participants engaged in a smartphone-based CBT program guided by bachelor's-level lay coaches. Primary outcomes were feasibility as evaluated by module completion and acceptability as evaluated by the Client Satisfaction Questionnaire-8 (CSQ-8]) and User Version of the Mobile Application Rating Scale (uMARS). Secondary outcomes included changes in the Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Appearance Anxiety Inventory, Skindex-16, and Psoriasis Symptom Inventory.</p><p><strong>Results: </strong>Of 30 participants, 63.3% completed ≥4/8 modules and 43.3% completed ≥6/8 modules. Mean CSQ-8 and uMARS scores were 27.2 (SD 4.5) and 4.0 (SD 0.7), respectively, supporting high satisfaction. Statistically and clinically significant improvements were observed in PHQ-9 (mean change -4.4; Cohen's d = 0.92), GAD-7 (-2.8; d = 0.63), and Skindex-16 symptoms (5.0; d = 0.78), emotions (10.0; d = 0.95), and functioning (6.4; Cohen's d = 0.71) subscales as well as the Psoriasis Symptom Inventory (3.1; d = 0.43).</p><p><strong>Conclusions: </strong>This study supports the feasibility, acceptability, and preliminary efficacy of smartphone-delivered CBT for individuals with psoriasis and depressive symptoms. Given the scalability of this model, future randomized trials are warranted to assess broader effectiveness in dermatology care settings.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251387099"},"PeriodicalIF":0.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12507800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copay Accumulators: A Legislative Issue in Dermatology.","authors":"Melissa C Leeolou, Justin L Jia, Dayna L Pham, Jason Harris, Wilson Liao","doi":"10.1177/24755303251361815","DOIUrl":"10.1177/24755303251361815","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251361815"},"PeriodicalIF":0.0,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Patient Priorities for Psoriatic Disease Research.","authors":"Georgia Marquez-Grap, Andrea Leung, Allison Kranyak, Krystal Adkins, Jessica Smith, Alicia O'Neal, Guy Eakin, Wilson Liao","doi":"10.1177/24755303251361816","DOIUrl":"10.1177/24755303251361816","url":null,"abstract":"<p><p><b>Background:</b> There have been significant advances in psoriatic disease research in recent years, leading to better understanding of genes involved and increased treatment options. <b>Purpose:</b> To guide current research priorities for psoriatic disease, we held an interactive session on this topic consisting of a presentation and small group discussion with National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. <b>Research design:</b> We presented a list of 10 psoriatic research topics and asked attendees to rate the priority of each topic on a 9-point scale. The session also included breakout groups where attendees discussed research areas most important to them. <b>Study Sample:</b> National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. <b>Data collection and/or Analysis:</b> Attendees completed an online REDCap survey which was then analyzed by the study team. <b>Results:</b> \"Improving treatment for psoriatic disease and achieving remission\" was the research topic that received the highest overall rating. We also learned of research topics of high patient interest not included on our original list of 10 topics, including research exploring the relationship between psoriatic disease and hormones, infertility, and menopause. Increased research on pediatric psoriatic disease and research initiatives focused on increased patient and provider education were topics of importance to attendees as well. <b>Conclusion:</b> Overall, these findings may help guide future patient-centered research agendas in psoriatic disease.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251361816"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics.","authors":"Alexandra Lauren Rice, Sarah Gillespie, Nikhil Sai, Soumya M Reddy, Joseph F Merola, Rebecca H Haberman, Alexis Ogdie, Jose U Scher","doi":"10.1177/24755303251361800","DOIUrl":"10.1177/24755303251361800","url":null,"abstract":"<p><strong>Background: </strong>In order to apply current treatment recommendations for psoriatic arthritis (PsA), a complete assessment of psoriatic disease domains must be completed by the clinician. This includes a musculoskeletal examination (including tender and swollen joints, dactylitis, enthesitis, and axial disease) as well as skin and nail examination. Documentation in the clinician's note serves as a proxy for disease assessment.</p><p><strong>Objective: </strong>To explore differences in documentation of psoriatic domains between PsA specialist and general rheumatologists at 2 academic centers.</p><p><strong>Methods: </strong>We identified PsA patients seen by either general rheumatologists or by PsA combined clinic specialist providers at 2 established PPACMAN (Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network) sites. Records were assessed for the presence (and extent) of documentation for musculoskeletal and cutaneous PsA domains. We also examined accuracy of ICD coded diagnoses to understand the extent to which discrete data from the electronic medical record can be used to evaluate completeness of assessment.</p><p><strong>Results: </strong>PsA combined clinic specialist providers documented disease domains significantly more consistently compared to generalists, including tender and swollen joint counts (<i>P</i> < 0.001), assessment of spondyloarthritis (<i>P</i> = 0.017), and presence/extent of skin involvement (<i>P</i> < 0.001). Additionally, PsA specialists more consistently coded for both psoriasis (PsO) and PsA.</p><p><strong>Conclusions: </strong>In this multicenter, retrospective study, compared to generalists, PsA combined-clinic specialist providers more thoroughly documented both musculoskeletal and cutaneous psoriatic disease domains and ICD coding of PsO for patients, highlighting gaps in assessment and documentation. These findings underscore the need for improved training in psoriatic disease assessment and simplified modalities for documentation.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251361800"},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey.","authors":"Omar Alani, Carrington Webb, Nashwah Memon, S Minhaj Rahman, Fahad Ahmed, Nicole Seminara, Adel Haque","doi":"10.1177/24755303251345804","DOIUrl":"10.1177/24755303251345804","url":null,"abstract":"<p><p>Biologic dosing frequency is a key concern among psoriasis (PsO) patients and physicians, yet dosing optimization remains a challenge. This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab (GUS) every 8 weeks, and ixekizumab (IXE) every 4 weeks, in managing PsO. This phone survey study evaluated 87 adults on RZB (n = 29), GUS (n = 35), or IXE (n = 23) from 2019 onward at two clinical sites. Patients were assessed for baseline PsO bothersome severity, current dosing frequency satisfaction, frequency of PsO flares, and preferred dosing frequency. Most patients were males (57.5%) with an average age of 54.1 years and an average treatment duration of 19.0 months. At baseline before treatment, 87% were 'very bothered' by their PsO. After treatment, 86% were either '3-somewhat' or '4-very satisfied' with their current dosing schedule, with no significant differences between each drug (<i>P</i> = 0.7). Across all biologics the majority of participants (62% with RZB, 57% with GUS, and 48% with IXE) preferred maintaining their current dosing frequency. No statistically significant differences were observed in dosing frequency preference between treatment groups, suggesting dosing schedule is not a primary concern for most patients. This aligns with previous research demonstrating effective disease control is the most important factor for patient satisfaction; however, tailoring dosing regimens to individual patient needs can also strengthen long-term adherence, as demonstrated in recent studies.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251345804"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}